- Home
- CDTG vs LSB Comparison
CDTG vs LSB Comparison
Compare CDTG & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- LSB
- Stock Information
- Founded
- CDTG 2012
- LSB 2002
- Country
- CDTG China
- LSB China
- Employees
- CDTG N/A
- LSB N/A
- Industry
- CDTG
- LSB
- Sector
- CDTG
- LSB
- Exchange
- CDTG NYSE
- LSB NYSE
- Market Cap
- CDTG 24.5M
- LSB 22.3M
- IPO Year
- CDTG 2024
- LSB N/A
- Fundamental
- Price
- CDTG N/A
- LSB N/A
- Analyst Decision
- CDTG
- LSB
- Analyst Count
- CDTG 0
- LSB 0
- Target Price
- CDTG N/A
- LSB N/A
- AVG Volume (30 Days)
- CDTG 746.4K
- LSB 24.1K
- Earning Date
- CDTG 05-15-2025
- LSB 07-15-2025
- Dividend Yield
- CDTG N/A
- LSB N/A
- EPS Growth
- CDTG N/A
- LSB N/A
- EPS
- CDTG 0.14
- LSB N/A
- Revenue
- CDTG $29,765,205.00
- LSB $79,415,311.00
- Revenue This Year
- CDTG N/A
- LSB $39.33
- Revenue Next Year
- CDTG N/A
- LSB $75.61
- P/E Ratio
- CDTG $4.90
- LSB N/A
- Revenue Growth
- CDTG N/A
- LSB N/A
- 52 Week Low
- CDTG $0.52
- LSB $0.36
- 52 Week High
- CDTG $4.64
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- LSB 45.97
- Support Level
- CDTG N/A
- LSB $0.89
- Resistance Level
- CDTG N/A
- LSB $1.12
- Average True Range (ATR)
- CDTG 0.00
- LSB 0.07
- MACD
- CDTG 0.00
- LSB 0.02
- Stochastic Oscillator
- CDTG 0.00
- LSB 45.70
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.